Myelophthisic Anemia Medication
- Author: Emmanuel C Besa, MD; Chief Editor: Koyamangalath Krishnan more...
Medication Summary
Correction of anemia often requires blood and/or blood products. The therapy is used to restore the hemodynamics of the vascular system and replace lost red blood cells. Major morbidities of anemia can be prevented by providing timely transfusion to restore hemoglobin to safe levels.
Blood Product Derivatives
Class Summary
Some agents in this category are used as needed to treat anemia.
Packed red blood cells
Packed red blood cells (PRBCs) are used preferentially to whole blood because they limit volume, immune, and storage complications. PRBCs have 80% less plasma, are less immunogenic, and can be stored for about 40 days (vs 35 d for whole blood). PRBCs are obtained after centrifugation of whole blood. Leukocyte-poor PRBCs are used in patients who are transplantation candidates/recipients or in those with prior febrile transfusion reactions. Washed or frozen PRBCs are used in individuals with hypersensitivity transfusion reactions.
Delsol G, Guiu-Godfrin B, Guiu M, Pris J, Corberand J, Fabre J. Leukoerythroblastosis and cancer frequency, prognosis, and physiopathologic significance. Cancer. Sep 1979;44(3):1009-13. [Medline].
Brochamer WL Jr, Keeling MM. The bone marrow biopsy, osteoscan, and peripheral blood in non-hematopoietic cancer. Cancer. Aug 1977;40(2):836-40. [Medline].
Makoni SN, Laber DA. Clinical spectrum of myelophthisis in cancer patients. Am J Hematol. May 2004;76(1):92-3. [Medline].
Bodem CR, Hamory BH, Taylor HM, Kleopfer L. Granulomatous bone marrow disease. A review of the literature and clinicopathologic analysis of 58 cases. Medicine (Baltimore). Nov 1983;62(6):372-83. [Medline].
Shamdas GJ, Ahmann FR, Matzner MB, Ritchie JM. Leukoerythroblastic anemia in metastatic prostate cancer. Clinical and prognostic significance in patients with hormone-refractory disease. Cancer. Jun 1 1993;71(11):3594-600. [Medline].

